Xceleron, a provider of ultra-sensitive analytical technology to novel clinical designs, has partnered with Crystal Pharmatech, a China-based CRO, to offer drug developers early bioavailability data to optimize solid-state forms and formulations. The partnership will combine accelerator mass spectrometry (AMS) technology and expertise aimed at cost-effectively removing pharmacokinetic uncertainty by providing better early clinical and solid-state information.
“At Xceleron, we believe that technology can get life-changing drugs to people who need them, sooner and at a lower cost. This partnership will help our clients do that by efficiently and cost-effectively answering critical questions earlier,” said Dr. Michael Butler, chief executive officer of Xceleron.
“Having robust bioavailability and pharmacokinetic data at the outset provides a strong foundation for determining the best solid form and formulation,” said Dr. Alex Chen, chief executive officer of Crystal Pharmatech. “Each company brings significant expertise to the discussion of novel clinical outcomes.”